Cargando…

Dual Antiplatelet Therapy with Parenteral P2Y(12) Inhibitors: Rationale, Evidence, and Future Directions

Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an inhibitor of the platelet P2Y(12) receptor for ADP, remains among the most investigated treatments in cardiovascular medicine. While a substantial amount of research initially stemmed from the observations of late and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alagna, Giulia, Mazzone, Paolo, Contarini, Marco, Andò, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144071/ https://www.ncbi.nlm.nih.gov/pubmed/37103042 http://dx.doi.org/10.3390/jcdd10040163

Ejemplares similares

Antiplatelet therapy in cardiovascular disease: Current status and future directions
por: Passacquale, Gabriella, et al.
Publicado: (2022)

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy—Current Data and Future Directions
por: Spinthakis, Nikolaos, et al.
Publicado: (2018)

Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors
por: Byun, Sungwook, et al.
Publicado: (2022)

P2Y12 Inhibitors Exacerbate Low-dose Aspirin-induced Small Bowel Injury in Dual Antiplatelet Therapy
por: Handa, Yukiko, et al.
Publicado: (2021)

Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines
por: Saven, Hannah, et al.
Publicado: (2022)

Role of pharmacists in providing parenteral nutrition support: current insights and future directions
por: Katoue, Maram Gamal
Publicado: (2018)

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
por: Valgimigli, Marco, et al.
Publicado: (2021)

Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions
por: Angiolillo, Dominick J.
Publicado: (2009)

Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review
por: Carciotto, Gabriele, et al.
Publicado: (2023)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review
por: Magnani, Giulia, et al.
Publicado: (2023)

The SEARCH for Diabetes in Youth Study: Rationale, Findings, and Future Directions
por: Hamman, Richard F., et al.
Publicado: (2014)

Impact of the Dual Antiplatelet Therapy Score on Clinical Outcomes in Acute Coronary Syndrome Patients Receiving P2Y12 Inhibitor Monotherapy
por: Huang, Sheng-Wei, et al.
Publicado: (2022)

Dual Antiplatelet Therapy in Coronary Artery Disease
por: Sharma, Raghav, et al.
Publicado: (2020)

Lipid emulsions in parenteral nutrition of intensive care patients: current thinking and future directions
por: Calder, Philip C., et al.
Publicado: (2010)

Ethical and legal points of view in parenteral nutrition – Guidelines on Parenteral Nutrition, Chapter 12
por: Rothaermel, S., et al.
Publicado: (2009)

Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent
por: Huseynov, Aydin, et al.
Publicado: (2019)

Personalized antiplatelet therapy with P2Y(12) receptor inhibitors: benefits and pitfalls
por: Winter, Max-Paul, et al.
Publicado: (2015)

The dogma of aspirin: a critical review of evidence on the best monotherapy after dual antiplatelet therapy
por: Polo Friz, Hernan, et al.
Publicado: (2015)

Sex-Related Bleeding Risk in Acute Coronary Syndrome Patients Receiving Dual Antiplatelet Therapy with Aspirin and a P2Y12 Inhibitor
por: ten Haaf, Monique E., et al.
Publicado: (2023)

Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome
por: Verdoia, Monica, et al.
Publicado: (2021)

Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field
por: De Servi, Stefano, et al.
Publicado: (2023)

Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome
por: Patti, Giuseppe, et al.
Publicado: (2017)

Magnetic Resonance Imaging Conditional Pacemakers: Rationale, Development and Future Directions
por: Cronin, Edmond M, et al.
Publicado: (2012)

Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
por: Wadosky, Kristine M, et al.
Publicado: (2016)

Impellent impeller—Switching intra‐aortic balloon pump to IMPELLA‐CP after ST‐segment elevation myocardial infarction and refractory cardiogenic shock
por: Contarini, Marco, et al.
Publicado: (2019)

Cardiovascular Safety of Celecoxib on Top of Dual Antiplatelet Therapy
por: Hong, Bum-Kee
Publicado: (2010)

Dental extraction in patients receiving dual antiplatelet therapy
por: Sánchez-Palomino, Paulino, et al.
Publicado: (2015)

Surgical tracheotomy performed with and without dual antiplatelet therapy
por: Markota, Andrej, et al.
Publicado: (2014)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

The use of dual antiplatelet therapy for ischemic cerebrovascular events
por: Mele, Francesco, et al.
Publicado: (2022)

Dual Antiplatelet Therapy: A Concise Review for Clinicians
por: Virk, Hafeez Ul Hassan, et al.
Publicado: (2023)

Aspirin Monotherapy beyond 12 Months of Dual Antiplatelet Therapy in Patients with Acute Myocardial Infarction: Oldies But Goodies?
por: Suh, Jung-Won
Publicado: (2019)

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial
por: Li, Yi, et al.
Publicado: (2020)

Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial
por: Helft, Gérard, et al.
Publicado: (2013)

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
Publicado: (2022)

Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
por: Feng, Wen-Han, et al.
Publicado: (2022)

Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
por: Shin, Eun-Seok, et al.
Publicado: (2023)

Improving use of proton pump inhibitors with dual antiplatelet therapy in patients admitted with acute coronary syndrome
por: Jinadu, Tomilola, et al.
Publicado: (2022)

Mindfulness Training for People With Dementia and Their Caregivers: Rationale, Current Research, and Future Directions
por: Berk, Lotte, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_72qfno57g3ul056nf1l3upmc47